Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Panipenem/betamipron.

Karen L Goa1, Stuart Noble

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|April 8, 2003
PubMed
Summary
This summary is machine-generated.

Panipenem/betamipron is an effective parenteral carbapenem antibiotic for various infections, demonstrating good clinical and bacteriological outcomes. This combination therapy showed favorable tolerability with minimal adverse events in diverse patient populations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trauma, identity and transition: evaluation of the RESLEAPS programme for retiring senior police officers.

Frontiers in psychiatry·2026
Same author

Erratum to: Maclobemide.

Drugs·2017
Same author

Erratum to: Moclobemide.

Drugs·2017
Same author

Erratum to: Cyclosporin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Immunoregulatory Disorders.

Drugs·2017
Same author

Once-monthly ibandronate.

Treatments in endocrinology·2005
Same author

Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.

Treatments in endocrinology·2005
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Panipenem is a parenteral carbapenem antibiotic with broad-spectrum activity against Gram-negative and Gram-positive bacteria.
  • It is administered with betamipron to prevent nephrotoxicity by inhibiting renal tubule uptake.
  • The combination targets infections caused by beta-lactamase-producing bacteria and Streptococcus pneumoniae.

Purpose of the Study:

  • To evaluate the clinical and bacteriological efficacy of panipenem/betamipron.
  • To assess the safety and tolerability of panipenem/betamipron in various patient groups.
  • To compare panipenem/betamipron with other antibiotics in specific patient populations.

Main Methods:

  • Large, randomized clinical trials in adults with respiratory and urinary tract infections.

Related Experiment Videos

  • Non-comparative trials in adults with surgical/gynecological infections and pediatric patients.
  • Small trials in elderly patients comparing efficacy against piperacillin and ofloxacin.

    • Main Results:

    • Panipenem/betamipron demonstrated good clinical and bacteriological efficacy, comparable to imipenem/cilastatin.
    • Effective in treating respiratory, urinary, surgical, and gynecological infections in adults.
    • Showed efficacy in pediatric patients and elderly patients with urinary and respiratory tract infections.

    Conclusions:

    • Panipenem/betamipron is a clinically effective and well-tolerated treatment option for a wide range of bacterial infections.
    • Its efficacy is comparable to established treatments like imipenem/cilastatin.
    • The combination therapy presents a favorable safety profile with generally mild adverse events.